Diamyd diabetes vaccine: Phase III amended

Next month, the company will expand enrollment to patients ages 10-16 in an ongoing, double-blind, placebo-controlled, U.S. Phase III trial evaluating subcutaneous Diamyd diabetes vaccine in about 320...